Topic
weight-loss drugs
27 stories related to this topic, newest first.
nbcnews.comscience6 days ago
Medicare to Cover Weight Loss Drugs for Adults 65 and Older Starting Next Month
The Trump administration will extend a transitional program called Bridge to provide coverage through the end of next year after private insurers declined to join a planned three-year demonstration.
app.buzzsumo.comscience10 days ago
Some Employers Plan to Drop GLP-1 Weight-Loss Drug Coverage in 2027 While Most Large Employers Retain It
Surveys show 5 to 10 percent of large employers intend to end coverage next year even as overall adoption of the medicines continues to rise.
Wiredtechnology10 days ago
Customers Report Unauthorized Charges From Telehealth Service Selling Compounded GLP-1 Drugs
Multiple users of FitRx and Zealthy, Inc. say they were charged for medication shipments they did not request. The company previously paid a $5 million settlement with the U.S. government over similar complaints.
The Guardianscience13 days ago
New Pancreatic Cancer Drug Doubles Survival Time in Trial
A daily pill extended median survival from 6.5 to 13.5 months for patients with advanced pancreatic cancer in a 500-person study. Separate early trials showed a smart drug shrank tumors in six common cancers, and observational data linked GLP-1 weight-loss drugs to lower cancer r…
ABC Newsworld18 days ago
Observational Study Links GLP-1 Use to 30% Lower Breast Cancer Rate, but Researchers Caution Findings Are Not Definitive
A University of Pennsylvania analysis of health records found women taking GLP-1 medications had about 30 percent lower incidence of breast cancer. The observational study adds to research on weight-loss drugs and cancer prevention.
newser.comscience18 days ago
Novo Nordisk Launches Wegovy Oral Weight-Loss Pill in UAE, First Market Outside the U.S.
The Danish drugmaker introduced its oral weight-loss treatment in the UAE on Wednesday, the first market outside the United States. The Emirates Drug Establishment approved the pill earlier this week for weight management and cardiovascular-risk reduction.
New York Postscience19 days ago
Observational Study of 110,000 Women Finds Association Between GLP-1 Drug Use and 30% Lower Breast Cancer Risk
University of Pennsylvania researchers found women aged 45-80 taking GLP-1 medications had a 30% lower likelihood of developing breast cancer. The analysis examined records from more than 110,000 participants in the typical age range for diagnosis.
english.elpais.comworld39 days ago
UK Obesity Rates Plateau After Decades of Increase
A global study led by Imperial College London found that obesity rates in the UK have stabilised in children since the early 2000s and are rising more slowly among adults. The analysis of data from 1980 to 2024 shows the UK remains among the top 10 high-income western nations for…
nbcnews.comworld40 days ago
Daily Pill Maintains 70% of Weight Loss vs 38-50% on Placebo One Year After Stopping GLP-1 Injections
A new study shows patients taking daily orforglipron kept more than 70 percent of prior weight loss after one year off jabs, compared with 38-50 percent for those on placebo. The Eli Lilly drug, already available in the US at around $149 per month for the lowest dose, offers a ch…
nypost.comscience40 days ago
Oral Orforglipron Maintains Modest Weight Loss After Stopping Injectables, Trial Finds
A Nature Medicine study found that daily oral orforglipron allowed patients to retain most of their weight reduction after stopping tirzepatide or semaglutide injections. The trial of 376 U.S. participants showed significantly better maintenance than placebo. The drug, approved l…
NA
benzinga.comfinance40 days ago
Hims & Hers Reports Q1 Revenue of $608M, Maintains 2025 Outlook Despite Wider Net Loss
The telehealth company reported weaker profitability and lower revenue per subscriber even as sales rose 4%. Hims & Hers issued full-year guidance of up to $3 billion in revenue while navigating its new partnership to sell branded Wegovy.
theconservativetreehouse.comworld40 days ago
Trump Administration Launches 18-Month Medicare Pilot Capping Copays at $50 for Certain GLP-1 Weight-Loss Drugs
President Donald Trump and the Centers for Medicare & Medicaid Services unveiled an 18-month pilot that will allow qualifying Medicare Part D beneficiaries to obtain certain GLP-1 medications such as Wegovy for $50 a month beginning July 1, 2026. The program marks a major policy…
pandaily.comworld43 days ago
Indian Firms Begin Selling Generic Semaglutide After Patent Expiration
Several pharmaceutical companies began selling lower-cost versions of semaglutide weight-loss drugs in India following the key patent's expiration in March. Mounjaro has become one of the top-selling drugs in a country with the world's second-highest number of overweight adults a…
manilatimes.networld44 days ago
Medicare to Test $50 Monthly Co-Pay for GLP-1 Weight Loss Drugs in New Pilot Program
The Centers for Medicare and Medicaid Services announced a two-year demonstration program that will allow certain enrollees to access FDA-approved GLP-1 medications for weight loss at a fixed $50 monthly co-pay with no deductible. The Medicare GLP-1 Bridge program runs from July…
AB
Semaforworld45 days ago
Novo Nordisk Says It Is Targeting Acquisitions Larger Than $10 Billion After Losing Metsera Bid to Pfizer
Novo Nordisk’s CFO said the company has the balance sheet to pursue bigger acquisitions but is constrained by the availability of suitable assets. The Danish drugmaker lost a messy bidding war for the weight-loss drug startup last year that included dueling lawsuits. Novo Nordisk…
manilatimes.netpolitics46 days ago
Made-in-China Agrees to Stop Selling GLP-1 Compounds in U.S., Pays $30,000 Penalty to Connecticut
The international online platform agreed to halt all sales of GLP-1 medications to U.S. customers and pay a suspended $300,000 penalty. Connecticut Attorney General William Tong said the drugs contained impurities and inconsistent active ingredients with no generic versions legal…
AB
Nprscience46 days ago
Medicare to Test 18-Month GLP-1 Pilot for Weight Loss Drugs Starting July 2026
The Centers for Medicare & Medicaid Services will begin a short-term pilot on July 1, 2026, allowing eligible beneficiaries to obtain certain GLP-1 medications for weight loss at a flat $50 copayment. The 18-month program bridges to a potential longer-term initiative in 2028 afte…
news18.comfinance47 days ago
French Regulator Fines Novo Nordisk and Eli Lilly Over Weight Loss Drug Ads
France's medicines regulator imposed fines on Novo Nordisk and Eli Lilly for misleading advertisements related to their weight loss drugs. The penalties come amid launches of oral GLP-1 medications in the U.S., with Novo Nordisk's Wegovy pill gaining early traction. Company execu…
forbes.comscience60 days ago
CMS Launches Medicaid Fraud Crackdown as Insurers Opt Out of Medicare Weight Loss Drug Pilot
The Centers for Medicare & Medicaid Services announced a nationwide effort to combat Medicaid fraud, requiring states to submit provider revalidation plans. Separately, health insurers declined to participate in a Medicare pilot program for discounted weight loss drugs, prompting…
ST
Substrate placeholder — needs reviewbusiness70 days ago
Tapatio Hot Sauce Sold to Highlander Partners Amid Rising Demand from Weight-Loss Drugs
The Tapatio hot sauce brand, founded in 1971 by Jose-Luis Saavedra, has been acquired by Highlander Partners, a Dallas-based private investment firm. The sale occurs as demand for hot sauces increases due to flavor cravings among users of GLP-1 weight-loss drugs like Ozempic. The…
Substrate placeholder — needs reviewworld73 days ago
Study Identifies Genetic Variations Influencing Response to Weight-Loss Drugs Wegovy and Mounjaro
Researchers analyzed genetic data from 15,000 individuals to identify variations linked to weight-loss outcomes and side effects from medications like Wegovy and Mounjaro. The study, published in Nature, found that certain variants affect weight reduction and nausea or vomiting s…
citizen.co.zafinance73 days ago
GLP-1 Weight Loss Drugs Drive Potential $13 Billion Boost in Apparel Retail Spending
Millions of individuals using GLP-1 drugs for weight loss are increasing their purchases of new clothing from retailers. Equity research firm Bernstein estimates this trend could generate up to $13 billion in annual spending for the apparel sector. The development highlights a gr…
Substrate placeholder — needs reviewworld73 days ago
Eli Lilly Launches Oral GLP-1 Medication Orforglipron for Weight Loss in the United States
Eli Lilly and Company has introduced Foundayo, the brand name for orforglipron, an oral GLP-1 receptor agonist approved for weight management. The pill offers a non-injectable alternative to existing treatments in the growing obesity drug market. Availability begins in the US, ta…
LI
sciencenews.orgscience74 days ago
Genetic Variants Linked to Weight Loss Outcomes and Side Effects from GLP-1 Drugs
A study published in Nature identifies variations in two genes associated with greater weight loss and increased side effects from GLP-1 receptor agonist drugs like Wegovy and Mounjaro. The research, based on data from 15,000 to nearly 28,000 23andMe users, shows modest genetic i…
ST
neurosciencenews.comscience74 days ago
Genetic Variants Linked to Weight Loss Outcomes on GLP-1 Drugs in New Study
A study published in Nature identifies variations in two genes associated with greater weight loss and side effects from GLP-1 receptor agonist drugs like Wegovy and Mounjaro. The research, based on data from 15,000 to 28,000 users, shows these genetic factors contribute modestly…
BU
ST
Hunted230 / Wikimedia (CC BY-SA 3.0)world76 days ago
First-Time Users of Weight-Loss Medicines Seek Lower Costs and Greater Convenience from Novo Nordisk and Eli Lilly Pills
Seven doctors specializing in obesity report that Americans beginning weight-loss treatments prioritize reduced costs and improved convenience. These patients are evaluating oral medications from Novo Nordisk and Eli Lilly. The preferences reflect ongoing discussions in the obesi…
RE
Substrate placeholder — needs reviewscience76 days ago
Rise in Testing of Unregulated Peptides in UK Amid Weight-Loss and Wellness Demand
Laboratories in the UK and internationally are processing thousands of samples of unregulated peptides sent by consumers for quality verification. These substances, often marketed for weight loss, biohacking, and anti-aging, include experimental compounds like retatrutide, which…